Selected trials of nonmyeloablative or reduced-intensity allogeneic transplantation for follicular or indolent non-Hodgkin lymphoma.
| Site . | No. patients . | Median age, y . | Median no. prior Rx . | Donor type . | Regimen . | Time, y/OS, % . | Time, y/PFS, % . | Reference . |
|---|---|---|---|---|---|---|---|---|
| *Subset of patients with low-grade NHL. | ||||||||
| Abbreviations: EBMT, ; COH, MRD, matched related donor; URD, unrelated donor; MUD, matched unrelated donor; Flu, fludarabine; Cy, cyclophosphamide; Ritux, Rituximab; Alemtuz, alemtuxumab; Mel, melphalan; TBI, total body irradiation; OS, overall survival; PFS, progression-free survival. | ||||||||
| Seattle consortium | 46* | 54 | 6 | MRD URD | Flu/TBI | 3/52 | 3/43 | Rezvani et al33 |
| MD Anderson | 20 | 51 | 2 | MRD | Flu/Cy +/– Ritux | 2/84 | 2/84 | Khouri et al34 |
| UK multicenter | 41* | 42 | 3 | MRD MUD | Flu/Mel Alemtuz | 3/73 | 3/65 | Morris et al36 |
| EBMT | 52* | 46 | 3 | MRD MUD | Various | 2/65 | 2/54 | Robinson et al37 |
| Japan | 45* | 48 | 4 | MRD MUD | Various | 3/79 | NA | Kusumi et al35 |
| COH | 16* | 51 | 2 | MRD URD | Flu/Mel | 2/68 | 2/49 | Rodriguez et al38 |
| Site . | No. patients . | Median age, y . | Median no. prior Rx . | Donor type . | Regimen . | Time, y/OS, % . | Time, y/PFS, % . | Reference . |
|---|---|---|---|---|---|---|---|---|
| *Subset of patients with low-grade NHL. | ||||||||
| Abbreviations: EBMT, ; COH, MRD, matched related donor; URD, unrelated donor; MUD, matched unrelated donor; Flu, fludarabine; Cy, cyclophosphamide; Ritux, Rituximab; Alemtuz, alemtuxumab; Mel, melphalan; TBI, total body irradiation; OS, overall survival; PFS, progression-free survival. | ||||||||
| Seattle consortium | 46* | 54 | 6 | MRD URD | Flu/TBI | 3/52 | 3/43 | Rezvani et al33 |
| MD Anderson | 20 | 51 | 2 | MRD | Flu/Cy +/– Ritux | 2/84 | 2/84 | Khouri et al34 |
| UK multicenter | 41* | 42 | 3 | MRD MUD | Flu/Mel Alemtuz | 3/73 | 3/65 | Morris et al36 |
| EBMT | 52* | 46 | 3 | MRD MUD | Various | 2/65 | 2/54 | Robinson et al37 |
| Japan | 45* | 48 | 4 | MRD MUD | Various | 3/79 | NA | Kusumi et al35 |
| COH | 16* | 51 | 2 | MRD URD | Flu/Mel | 2/68 | 2/49 | Rodriguez et al38 |